George DeMaagd, Ashok Philip. Parkinson’s disease and its management. Pharm Therap 2015; 40(8): 504-32.
De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006; 5: 525-35.
Dorsey ER, Constantinescu R, Thompson JP. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurol 2007; 68(3): 84-6.
Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurol 2011; 76(10): 863-9.
Howland RH. Transdermal selegiline: A novel MAOI formulation for depression. J Psychosoc Nurs Ment Health Serv 2006; 44: 9-12.
Nyholm D. Pharmacokinetic optimization in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006; 45: 109-36.
Lee KC, Chen JJ. Transdermal Selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007; 3(5): 527-37.
BarbiMda S. Carvalho FC, Kiill CP, BarudHda S, Santagneli SH, Ribeiro SJ, Gremião MP. Preparation and characterization of chitosan nanoparticles for zidovudine nasal delivery. J Nanosci Nanotechnol 2015; 15(1): 865-74.
Fonseca-Santos B, Gremião MPD, Chorilli M. Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 2015; 10: 4981-5003.
Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010; 40(5): 385-403.
Wilson B, Samanta M, Santhi K, Sampath Kumar K, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008; 70: 75-84.
HoLun Wong, Xiao Yu Wu, Reina Bendayan. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64: 686-700.
Susana R, Ana M. Rosa da Costab, Ana Grenha. Chitosan/carrageenan nanoparticles: effect of cross-linking with tripolyphosphate and charge ratios. Carbohydr Polym 2012; 89: 282-9.
Haque S, Shadab MD, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: Pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012; 89: 72-9.
Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces 2012; 90: 21-7.
Fazil M, Shadab M, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012; 47: 6-15.
Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 2016; 23: 130-9.
Md S, Khan RA, Mustafa G, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2013; 48: 393-405.
Sonal S, Tushar M, Mohammad T, Razdan BK, Talegaonkar S. Appraisal of transdermal water-in-oil nanoemulgel of selegiline HCl for the effective management of Parkinson’s disease: pharmacodynamic, pharmacokinetic and biochemical investigations. AAPS PharmSciTech 2017; 1-17.
Luthra PM, Barodia SK, Raghubir R. Antagonism of haloperidol-induced swim impairment in l-dopa and caffeine treated mice. A pre-clinical model to study Parkinson’s disease. J Neurosci Methods 2009; 178: 284-90.
Harini Chowdary V, Prasanna Raju Y, Basaveswara MVR, Jyotsna T, Vandana KR, Sundaresan CR. Potential of microemulsified entacapone drug delivery systems in the management of acute Parkinson’s disease. J Acu Diseas 2016; 5(4): 315-25.
Josephine J, Vijaya C, Wilson B. Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug efavirenz. Int J Pharm Investig 2014; 4(3): 142-8.
Ekambaram P, Sathali AA. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011; 3: 216-20.